Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Amends Deal with Hana Biosciences for Non-RNAi Legacy Products

Premium

Tekmira Pharmaceuticals said this week that it has amended its licensing deal with Hana Biosciences for three non-RNAi chemotherapy drug candidates in a move that will eliminate future payments to former debt holders.

In 2006, Tekmira licensed the legacy products to Hana, which assumed all expenses associated with their development in exchange for milestones and royalties. Under the terms of the amended deal, Hana will make a $5.75 million payment to Tekmira, which has agreed to reduce certain future payments associated with the drugs.

Tekmira said it would transfer the money to former debt holders in order to eliminate future payments to these debt holders.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.